SCHEDULE 13G/A: Alger Associates, Inc. Amends Forte Biosciences Stake to 17.7%

Alger Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 17.7% of Forte Biosciences, Inc.'s common stock as of December 31, 2024.

Summary

• Alger Associates, Inc. reported beneficial ownership of 1,133,944 shares of Forte Biosciences, Inc. common stock.
• This ownership represents 17.7% of the total class of securities.
• The filing is an Amendment No. 4 to a previous Schedule 13G.
• Alger Associates, Inc. holds sole voting power over 1,112,322 shares and sole dispositive power over 1,133,944 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter sentiment, beyond confirming a significant institutional stake.

Positives

• A significant institutional investor, Alger Associates, Inc., holds a substantial 17.7% stake in Forte Biosciences, Inc., which may signal confidence in the company.

Future Outlook

The document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

This filing is a routine disclosure by an institutional investment manager, Alger Associates, Inc., detailing its significant passive ownership stake in Forte Biosciences, Inc., a company in the biotechnology sector. Such disclosures provide transparency on major shareholder positions within publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.

Key Dates

Keywords

Forte Biosciences, Alger Associates, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake